Details of proposed European PFAS ban released Today, the European Chemicals Agency (ECHA) published details of a proposed ban on the production, use, sale and import of some 10,000 per- and polyfluoroalkyl substances (PFAS).
COVID-19 vaccine uptake related to neighbourhood demographics COVID-19 vaccine uptake was lower in neighbourhoods that had proportionately higher percentages of residents from a non-Western migration background and residents who were more likely to vote for right-wing Christian and right-wing conservative political parties. iStock
Vaccination coverage for autumn round: Downward trend in Health & Welfare sector continues – 69% of nationwide medical high-risk groups were vaccinated At the start of the autumn round, from mid-September 2022, the first group to be offered a repeat vaccination against COVID-19 was people with an elevated risk of a severe course of illness and care workers who have contact with patients and/or clients
Proposed European PFAS ban officially submitted The Netherlands, Germany, Denmark, Sweden and Norway today took the first formal step towards a European ban on per- and polyfluoroalkyl substances (PFAS) by jointly submitting a restriction proposal to the European Chemicals Agency (ECHA).
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
New method for toxicological assessment of perfluoro mixtures Perfluoro (PFAS) is a group of substances that contains PFOS, PFOA and GenX. Perfluoro substances often occur as pollution in ground water and drinking water.
Large increase in legionellosis in the Netherlands The Municipal Public Health Services (GGD) received 561 reports of legionellosis over the past year. Never before has RIVM registered as many reports of this disease as in the past year.
Meningococcal type W most notable infectious disease in 2017 The report ‘State of Infectious Diseases in the Netherlands in 2017’ published by RIVM today, provides an overview of the most important developments in infectious diseases in the Netherlands and a